85 related articles for article (PubMed ID: 21924609)
21. Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.
Oballa RM; Belair L; Black WC; Bleasby K; Chan CC; Desroches C; Du X; Gordon R; Guay J; Guiral S; Hafey MJ; Hamelin E; Huang Z; Kennedy B; Lachance N; Landry F; Li CS; Mancini J; Normandin D; Pocai A; Powell DA; Ramtohul YK; Skorey K; Sørensen D; Sturkenboom W; Styhler A; Waddleton DM; Wang H; Wong S; Xu L; Zhang L
J Med Chem; 2011 Jul; 54(14):5082-96. PubMed ID: 21661758
[TBL] [Abstract][Full Text] [Related]
22. Discovery of triazolone derivatives as novel, potent stearoyl-CoA desaturase-1 (SCD1) inhibitors.
Sun S; Zhang Z; Pokrovskaia N; Chowdhury S; Jia Q; Chang E; Khakh K; Kwan R; McLaren DG; Radomski CC; Ratkay LG; Fu J; Dales NA; Winther MD
Bioorg Med Chem; 2015 Feb; 23(3):455-65. PubMed ID: 25555732
[TBL] [Abstract][Full Text] [Related]
23. Novel spiropiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4'-piperidine].
Uto Y; Kiyotsuka Y; Ueno Y; Miyazawa Y; Kurata H; Ogata T; Deguchi T; Yamada M; Watanabe N; Konishi M; Kurikawa N; Takagi T; Wakimoto S; Kono K; Ohsumi J
Bioorg Med Chem Lett; 2010 Jan; 20(2):746-54. PubMed ID: 20006498
[TBL] [Abstract][Full Text] [Related]
24. Discovery of Cytochrome P450 4F11 Activated Inhibitors of Stearoyl Coenzyme A Desaturase.
Winterton SE; Capota E; Wang X; Chen H; Mallipeddi PL; Williams NS; Posner BA; Nijhawan D; Ready JM
J Med Chem; 2018 Jun; 61(12):5199-5221. PubMed ID: 29869888
[TBL] [Abstract][Full Text] [Related]
25. Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part II: Identification of 4-ethylamino-3-(2-hydroxyethoxy)-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide and its biological evaluation.
Uto Y; Ogata T; Kiyotsuka Y; Miyazawa Y; Ueno Y; Kurata H; Deguchi T; Yamada M; Watanabe N; Takagi T; Wakimoto S; Okuyama R; Konishi M; Kurikawa N; Kono K; Osumi J
Bioorg Med Chem Lett; 2009 Aug; 19(15):4159-66. PubMed ID: 19541482
[TBL] [Abstract][Full Text] [Related]
26. Discovery of liver-targeted inhibitors of stearoyl-CoA desaturase (SCD1).
Deng Y; Yang Z; Shipps GW; Lo SM; West R; Hwa J; Zheng S; Farley C; Lachowicz J; van Heek M; Bass AS; Sinha DP; Mahon CR; Cartwright ME
Bioorg Med Chem Lett; 2013 Feb; 23(3):791-6. PubMed ID: 23265904
[TBL] [Abstract][Full Text] [Related]
27. Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity.
Iida T; Ubukata M; Mitani I; Nakagawa Y; Maeda K; Imai H; Ogoshi Y; Hotta T; Sakata S; Sano R; Morinaga H; Negoro T; Oshida S; Tanaka M; Inaba T
Eur J Med Chem; 2018 Oct; 158():832-852. PubMed ID: 30248655
[TBL] [Abstract][Full Text] [Related]
28. N-benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors.
Atkinson KA; Beretta EE; Brown JA; Castrodad M; Chen Y; Cosgrove JM; Du P; Litchfield J; Makowski M; Martin K; McLellan TJ; Neagu C; Perry DA; Piotrowski DW; Steppan CM; Trilles R
Bioorg Med Chem Lett; 2011 Mar; 21(6):1621-5. PubMed ID: 21324691
[TBL] [Abstract][Full Text] [Related]
29. A novel assay of cellular stearoyl-CoA desaturase activity of primary rat hepatocytes by HPLC.
Su C; Gullberg H; Simko H; Luthman M; Edlund PO; Lundbäck T
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Sep; 878(26):2427-32. PubMed ID: 20732836
[TBL] [Abstract][Full Text] [Related]
30. Recent progress in the discovery and development of stearoyl CoA desaturase inhibitors.
Uto Y
Chem Phys Lipids; 2016 May; 197():3-12. PubMed ID: 26344107
[TBL] [Abstract][Full Text] [Related]
31. Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors.
Xin Z; Zhao H; Serby MD; Liu B; Liu M; Szczepankiewicz BG; Nelson LT; Smith HT; Suhar TS; Janis RS; Cao N; Camp HS; Collins CA; Sham HL; Surowy TK; Liu G
Bioorg Med Chem Lett; 2008 Aug; 18(15):4298-302. PubMed ID: 18632269
[TBL] [Abstract][Full Text] [Related]
32. 4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: part 2. Pyridazine-based analogs.
Yang SM; Tang Y; Rano T; Lu H; Kuo GH; Gaul MD; Li Y; Ho G; Lang W; Conway JG; Liang Y; Lenhard JM; Demarest KT; Murray WV
Bioorg Med Chem Lett; 2014 Mar; 24(5):1437-41. PubMed ID: 24405703
[TBL] [Abstract][Full Text] [Related]
33. 4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: urea-based analogs.
Yang SM; Tang Y; Zhang R; Lu H; Kuo GH; Gaul MD; Li Y; Ho G; Conway JG; Liang Y; Lenhard JM; Demarest KT; Murray WV
Bioorg Med Chem Lett; 2013 Dec; 23(24):6773-6. PubMed ID: 24153205
[TBL] [Abstract][Full Text] [Related]
34. Discovery of 1-(4-phenoxypiperidin-1-yl)-2-arylaminoethanone stearoyl-CoA desaturase 1 inhibitors.
Zhao H; Serby MD; Smith HT; Cao N; Suhar TS; Surowy TK; Camp HS; Collins CA; Sham HL; Liu G
Bioorg Med Chem Lett; 2007 Jun; 17(12):3388-91. PubMed ID: 17434733
[TBL] [Abstract][Full Text] [Related]
35. Benzimidazole-carboxamides as potent and bioavailable stearoyl-CoA desaturase (SCD1) inhibitors from ligand-based virtual screening and chemical optimization.
Matter H; Zoller G; Herling AW; Sanchez-Arias JA; Philippo C; Namane C; Kohlmann M; Pfenninger A; Voss MD
Bioorg Med Chem Lett; 2013 Mar; 23(6):1817-22. PubMed ID: 23395660
[TBL] [Abstract][Full Text] [Related]
36. Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome.
Zhang Z; Sun S; Kodumuru V; Hou D; Liu S; Chakka N; Sviridov S; Chowdhury S; McLaren DG; Ratkay LG; Khakh K; Cheng X; Gschwend HW; Kamboj R; Fu J; Winther MD
J Med Chem; 2013 Jan; 56(2):568-83. PubMed ID: 23245208
[TBL] [Abstract][Full Text] [Related]
37. Tumor-Activated Benzothiazole Inhibitors of Stearoyl-CoA Desaturase.
Williams NS; Gonzales S; Naidoo J; Rivera-Cancel G; Voruganti S; Mallipeddi P; Theodoropoulos PC; Geboers S; Chen H; Ortiz F; Posner B; Nijhawan D; Ready JM
J Med Chem; 2020 Sep; 63(17):9773-9786. PubMed ID: 32787093
[TBL] [Abstract][Full Text] [Related]
38. High-throughput scintillation proximity assay for stearoyl-CoA desaturase-1.
Tawa P; Falgueyret JP; Guiral S; Isabel E; Powell DA; Zuck P; Skorey K
J Biomol Screen; 2011 Jun; 16(5):506-17. PubMed ID: 21406617
[TBL] [Abstract][Full Text] [Related]
39. Stearoyl-CoA desaturase inhibitors: update on patented compounds.
Liu G
Expert Opin Ther Pat; 2009 Sep; 19(9):1169-91. PubMed ID: 19691439
[TBL] [Abstract][Full Text] [Related]
40. 1,2,3-Triazole-containing uracil derivatives with excellent pharmacokinetics as a novel class of potent human deoxyuridine triphosphatase inhibitors.
Miyakoshi H; Miyahara S; Yokogawa T; Endoh K; Muto T; Yano W; Wakasa T; Ueno H; Chong KT; Taguchi J; Nomura M; Takao Y; Fujioka A; Hashimoto A; Itou K; Yamamura K; Shuto S; Nagasawa H; Fukuoka M
J Med Chem; 2012 Jul; 55(14):6427-37. PubMed ID: 22715973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
